Dosing schedules for pneumococcal conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 33, Issue SUPPL. 2, 2014, Pages

  Whitney, Cynthia G ^a   Goldblatt, David ^b   O'Brien, Katherine L ^c  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b Institute for Child Health   (United Kingdom)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Children; Disease prevention; Pneumococcal vaccine; Policy

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; LOWEST INCOME GROUP; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

CHILD, PRESCHOOL; HEALTH POLICY; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; UNITED STATES; VACCINES, CONJUGATE;

EID: 84891403870     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000076     Document Type: Article

References (72)

1. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2000;49(RR-9):1-35.
2. GAVI Alliance. GAVI Alliance. 2012. Available at: http://www. gavialliance. org/. Accessed December 6, 2012.
3. World Health Organization, United Nations Childrens Fund. Global Action Plan for Prevention and Control of Pneumonia (GAPP). Geneva, Switzerland: WHO Press; 2009.
4. Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children -use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2010;59(RR11):1-18.
5. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
6. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355-361.
7. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization -WHO position paper. Wkly Epidemiol Rec. 2007;82:93-104.
8. Klugman KP, Madhi SA, Huebner RE, et al.; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348.
9. World Health Organization. Pneumococcal vaccines WHO position paper -2012. Wkly Epidemiol Rec 2012;87:129-44.
10. Robinson KA, Baughman W, Rothrock G, et al.; Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729-1735.
11. World Health Organization, UNICEF. Global immunization data. October 2012. Available at: http://www.who.int/immunization-monitoring/Global- Immunization-Data.pdf. Accessed April 9, 2013.
12. M cEllistrem MC, Nahm MH. Novel pneumococcal serotypes 6C and 6D: anomaly or harbinger. Clin Infect Dis. 2012;55:1379-1386.
13. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348
14. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5:83-93.
15. Klugman KP, Madhi SA, Adegbola RA, et al. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine. 2011;29:3372-3373.
16. Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006;25:494-501.
17. Abdullahi O, Karani A, Tigoi CC, et al. The prevalence and risk factors for pneumococcal colonization of the nasopharynx among children in Kilifi District, Kenya. PLoS One. 2012;7:e30787.
18. O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis. 2007;196:1211-1220.
19. Deloria Knoll M, Park D, Johnson TS, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J. 2014;33 (Suppl 2):S119-S129.
20. Rückinger S, Dagan R, Albers L, et al. Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis. Vaccine. 2011;29:9600-9606.
21. Scott P, Rutjes AW, Bermetz L, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine. 2011;29:9711-9721.
22. Russell FM, Balloch A, Tang ML, et al. Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine. 2009;27:5685-5691.
23. Silfverdal SA, Hogh B, Bergsaker MR, et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J. 2009;28:e276-e282.
24. Fleming-Dutra KE, Conklin L, Loo JD, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J. 2014;33 (Suppl 2):S152-S160.
25. Dagan R, Givon-Lavi N, Porat N, et al. The effect of an alternative reduceddose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine. 2012;30:5132-5140.
26. Klugman KP, Black S, Dagan R, et al. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Amsterdam: Elsevier Saunders; 2012.
27. Ota MO, Akinsola A, Townend J, et al. The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. Vaccine. 2011;29:2999-3007.
28. Russell FM, Carapetis JR, Satzke C, et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vaccine Immunol. 2010;17:1970-1976.
29. P elton SI, Weycker D, Klein JO, et al. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine. 2010;28:1575-1582.
30. P ark SY, Van Beneden CA, Pilishvili T, et al.; Active Bacterial Core surveillance team. Invasive pneumococcal infections among vaccinated children in the United States. J Pediatr. 2010;156:478-483.e2.
31. Goldblatt D, Southern J, Ashton L, et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr Infect Dis J. 2010;29:401-405.
32. P ark DE, Johnson TS, Nonyane BAS, et al. The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. Pediatr Infect Dis J. 2014;33 (Suppl 2):S130-S139.
33. Scott JA, Ojal J, Ashton L, et al. Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis. 2011;53:663-670.
34. Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr Infect Dis J. 2010;29:756-762.
35. van Gils EJ, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA. 2009;302:159-167.
36. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
37. Cutts FT, Zaman SM, Enwere G, et al.; Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365: 1139-1146.
38. P almu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381:214-222.
39. L ucero MG, Nohynek H, Williams G, et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, doubleblind, placebo-controlled trial. Pediatr Infect Dis J. 2009;28:455-462.
40. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25:779-781.
41. O'Brien KL. The effect of conjugate pneumococcal vaccine on pneumonia and otitis media among Navajo and White Mountain Apache children. 3rd International Symposium on Pneumococci and Pneumococcal Diseases; 2002; Helsinki, Finland.
42. Tregnaghi MW, Sáez-Llorens X, López P, et al. Evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiDCV) against community-acquired pneumonia in Latin America. European Society of Pediatric Infectious Disease; June 7-11, 2011; The Hague, Netherlands.
43. Loo JD, Conklin L, Fleming-Dutra KE, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J. 2014;33 (Suppl 2):S140-S151.
44. E sposito S, Lizioli A, Lastrico A, et al. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. Respir Res. 2007;8:12.
45. Conklin L, Loo JD, Kirk J, et al. Systematic review of pneumococcal conjugate vaccine dosing schedules' effect on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J. 2014;33 (Suppl 2):S109-S118.
46. KEMRI/Wellcome Trust. The Pneumococcal Conjugate Vaccine Impact Study (PCVIS). Available at: http://www.kemri-wellcome.org/index.php/en/studies-inner/ 75. Accessed October 15, 2013.
47. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008;121:562-569.
48. O'Brien KL, Shaw J, Weatherholtz R, et al. Epidemiology of invasive Streptococcus pneumoniae among Navajo children in the era before use of conjugate pneumococcal vaccines, 1989-1996. Am J Epidemiol. 2004;160:270-278.
49. L acapa R, Bliss SJ, Larzelere-Hinton F, et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis. 2008;47:476-484.
50. Davidson M, Parkinson AJ, Bulkow LR, et al. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990 -ethnic differences and opportunities for prevention. J Infect Dis. 1994;170:368-376.
51. T orzillo PJ, Hanna JN, Morey F, et al. Invasive pneumococcal disease in central Australia. Med J Aust. 1995;162:182-186.
52. Weatherholtz R, Millar EV, Moulton LH, et al. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis. 2010;50:1238-1246.
53. Wenger JD, Zulz T, Bruden D, et al. Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply. Pediatr Infect Dis J. 2010;29:251-256.
54. O'Grady KA, Lee KJ, Carlin JB, et al. Increased risk of hospitalization for acute lower respiratory tract infection among Australian indigenous infants 5-23 months of age following pneumococcal vaccination: a cohort study. Clin Infect Dis. 2010;50:970-978.
55. Australian Government Department of Health and Aging. National immunisation program schedule. March 7, 2013; Available at: http://www.health. gov.au/internet/immunise/publishing.nsf/Content/nips-1. Acccessed April 29 2013
56. Russell FM, Carapetis JR, Balloch A, et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine. 2010;28:3341-3349.
57. M adhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007;25:2451-2457.
58. M adhi S, Cohen C, von Gottberg A. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: Translating research into policy. Vaccine. 2012;30(suppl 3):C23-C27.
59. Goldblatt D, Assari T. Module 9: Haemophilus influenzae type b. World Health Organisation Immunological Basis of Immunization Series. Geneva: World Health Organization; 2007.
60. Stoecker C, Hampton LM, Link-Gelles R, Messonnier ML, Zhou F, Moore MR. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics. 2013;132:e324-32. doi: 10.1542/peds.2012-3350. Epub 2013 Jul 1.
61. U.S. Food and Drug Administration. Vaccines, blood & biologics: Prevnar 13. September 17, 2012. Available at: http://www.fda.gov/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm. Accepted December 6, 2012.
62. E uropean Medicines Agency. Prevenar 13: pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed). September 5, 2012. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 001104/human-med-001220.jsp&mid=WC0b01ac058001d124. Accessed December 4, 2012.
63. E uropean Medicines Agency. Synflorix: pneumococcal polysaccharide conjugate vaccine (adsorbed). February 20, 2012; Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000973/human-med-001071.jsp&mid=WC0b01ac058001d124. Accessed December 4, 2012.
64. World Health Organization. WHO prequalified vaccines: filterable search for prequalified vaccines with product details. 2011. Available at: http://www.who.int/immunization-standards/vaccine-quality/PQ-vaccine-list-en/en/ index.html. Accessed December 4, 2012.
65. M arshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26: 496-500.
66. World Health Organization, Unicef. Estimated coverage by country, year, and vaccine. July 14, 2012. Available at: http://apps.who.int/immunization- monitoring/en/globalsummary/timeseries/tswucoveragedtp3.htm. Accessed December 7, 2012.
67. Rozenbaum M, Sanders E, van Hoek A, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. Brit Med J. 2010;340.
68. Daniels N, Valencia-Mendoza A, Gelpi A, et al. The art of public health: pneumococcal vaccine coverage in Mexico. Lancet. 2010;375:114-115.
69. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28(4 suppl):S66-S76.
70. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7:597-606.
71. Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center (IVAC). VIMS Report: Global Vaccine Introduction. October 2012:10.
72. World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2013 global summary. 2013. Available at: http://apps.who.int/ immunization-monitoring/globalsummary/schedules. Accessed June 12, 2013.